Literature DB >> 31580393

Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply.

Fiamma Berner1, David Bomze1, Lukas Flatz1.   

Abstract

Year:  2019        PMID： 31580393     DOI： 10.1001/jamaoncol.2019.4055

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  4 in total

Review 1.  Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.

Authors:  R Zou; Y Wang; S Cui; F Ye; X Zhang; M Wang
Journal:  Clin Transl Oncol       Date:  2021-05-17       Impact factor: 3.405

Review 2.  Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy.

Authors:  Elena Goleva; Taras Lyubchenko; Lukas Kraehenbuehl; Mario E Lacouture; Donald Y M Leung; Jeffrey A Kern
Journal:  Ann Allergy Asthma Immunol       Date:  2021-03-11       Impact factor: 6.248

3.  Inflammatory markers in autoimmunity induced by checkpoint inhibitors.

Authors:  Beate Husain; Michael Constantin Kirchberger; Michael Erdmann; Sabine Schüpferling; Amir-Reza Abolhassani; Waltraud Fröhlich; Carola Berking; Lucie Heinzerling
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-10       Impact factor: 4.553

4.  Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution.

Authors:  R Kleef; R Nagy; A Baierl; V Bacher; H Bojar; D L McKee; R Moss; N H Thoennissen; M Szász; T Bakacs
Journal:  Cancer Immunol Immunother       Date:  2020-11-05       Impact factor: 6.968
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.